Effects of lipophilic statins for heart failure: A meta-analysis of 13 randomised controlled trials

Heart Lung and Circulation

Volumn 23, Issue 10, 2014, Pages 970-977

  Liu, Gang ^a   Zheng, Xin Xin ^a   Xu, Yan Lu ^a   Lu, Jie ^a   Hui, Ru Tai ^a   Huang, Xiao Hong ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Heart failure; Lipophilic; Meta analysis; Mortality; Statins

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE;

AGE; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; BLOOD; DISEASE COURSE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MORTALITY; PATHOPHYSIOLOGY;

CHOLESTEROL, LDL; DISEASE PROGRESSION; HEART FAILURE; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84907800562     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.05.005     Document Type: Article

References (33)

1. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 Of The European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
2. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109(Suppl):e39-e43.
3. Givertz M.M., Colucci W.S. New targets for heart-failure therapy: Endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998, 352(Suppl):e34-e38.
4. Vrtovec B., Okrajsek R., Golicnik A., Ferjan M., Starc V., Schlegel T.T., et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008, 14:140-144.
5. Yamada T., Node K., Mine T., Morita T., Kioka H., Tsukamoto Y., et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: A prospective randomized controlled study. Am Heart J 2007, 153(suppl):e1051-e1058.
6. Abulhul E., McDonald K., Martos R., Phelan D., Spiers J.P., Hennessy M., et al. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: Effects on elevated serum markers of collagen turnover, inflammation, and b-type natriuretic peptide. Clin Ther 2012, 34:91-100.
7. Xie R.Q., Cui W., Liu F., Yang C., Pei W.N., Lu J.C. Statin therapy shortens qtc, qtcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol 2010, 140:255-257.
8. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G., Cornel J.H., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
9. Gissi H.F.I., Tavazzi L., Maggioni A.P., Barlera S., Franzosi M.G., Latini R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
10. Kjaergard L.L., Villumsen J., Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001, 135:982-989.
11. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
12. Node K., Fujita M., Kitakaze M., Hori M., Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839-843.
13. Hamaad A., Sosin M., Lip G.Y., MacFadyen R.J. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 2005, 19:183-187.
14. Hong Y.J., Jeong M.H., Hyun D.W., Hur S.H., Kim K.B., Kim W., et al. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005, 95:619-622.
15. Vrtovec B., Okrajsek R., Golicnik A., Ferjan M., Starc V., Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005, 11:684-690.
16. Sola S., Mir M.Q., Lerakis S., Tandon N., Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006, 47:332-337.
17. Wojnicz R., Wilczek K., Nowalany-Kozielska E., Szyguła-Jurkiewicz B., Nowak J., Poloński L., et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006, 97:899-904.
18. Bielecka-Dabrowa A., Goch J.H., Mikhailidis D.P., Rysz J., Maciejewski M., Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 2009, 15:12-23.
19. Horwich T.B., Middlekauff H.R., Maclellan W.R., Fonarow G.C. Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: A double-blind placebo-controlled trial. J Card Fail 2011, 17:879-886.
20. Takano H., Mizuma H., Kuwabara Y., Sato Y., Shindo S., Kotooka N., et al. Effects of pitavastatin in Japanese patients with chronic heart failure: The pitavastatin heart failure study (PEARL study). Circ J 2013, 77:917-925.
21. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol 2005, 19:117-125.
22. Nezasa K., Higaki K., Matsumura T., Inazawa K., Hasegawa H., Nakano M., et al. Liver-specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin. Drug Metab Dispos 2002, 30:1158-1163.
23. Komatsu T., Tachibana H., Sato Y., Ozawa M., Kunugita F., Nakamura M. Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: Comparison between atorvastatin and pravastatin. Int Heart J. 2011, 52:359-365.
24. Kim M.C., Ahn Y., Jang S.Y., Cho K.H., Hwang S.H., Lee M.G., et al. Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. Korean J Intern Med 2011, 26:294-303.
25. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
26. Gao L., Wang W., Li Y.L., Schultz H.D., Liu D., Cornish K.G., et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure. Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005, 112:1763-1770.
27. Tsutamoto T., Sakai H., Ibe K., Yamaji M., Kawahara C., Nakae I., et al. Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J 2011, 75:2160-2166.
28. Hobbs F.D., Roalfe A.K., Davis R.C., Davies M.K., Hare R. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007, 28:1128-1134.
29. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
30. Wagner A.H., Kohler T., Ruckschloss U., Just I., Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-COA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000, 20:61-69.
31. Hognestad A., Aukrust P., Wergeland R., Stokke O., Gullestad L., Semb A.G., et al. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 2004, 27:199-203.
32. Mason R.P. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006, 98:34-41.
33. Rinfret S., Behlouli H., Eisenberg M.J., Humphries K., Tu J.V., Pilote L. Class effects of statins in elderly patients with congestive heart failure: A population-based analysis. Am Heart J 2008, 155:316-323.